REPLAY | Lumos Diagnostics 1H FY26 Investor Briefing
9 March 2026
Lumos Diagnostics recently hosted an investor webinar covering its 1H FY26 financial results and operational progress.
During the first half of FY26, Lumos achieved several important milestones, including securing a US$317M exclusive U.S. distribution agreement for FebriDx®, submitting its CLIA waiver application to the U.S. FDA, and achieving Medicare reimbursement coverage across all U.S. jurisdictions. The Company also reported growing FebriDx revenue and positive operating cash flow.
In this session, CEO Doug Ward and CFO Barrie Lambert discuss Lumos’ half-year performance, recent commercial and regulatory milestones, and the key priorities ahead as Lumos works toward CLIA waiver for FebriDx and broader market expansion.
Watch video
During the first half of FY26, Lumos achieved several important milestones, including securing a US$317M exclusive U.S. distribution agreement for FebriDx®, submitting its CLIA waiver application to the U.S. FDA, and achieving Medicare reimbursement coverage across all U.S. jurisdictions. The Company also reported growing FebriDx revenue and positive operating cash flow.
In this session, CEO Doug Ward and CFO Barrie Lambert discuss Lumos’ half-year performance, recent commercial and regulatory milestones, and the key priorities ahead as Lumos works toward CLIA waiver for FebriDx and broader market expansion.
Watch video
